Bartley P Griffith

Prof. Bartley P Griffith


Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2022 in New England Journal of Medicine
Verified
Journal Article
Closed access
BGBartley P Griffith
Bartley P Griffith
CGCorbin E. Goerlich
Corbin E. Goerlich
ASAvneesh K. Singh
Avneesh K. Singh
MRMartine Rothblatt
Martine Rothblatt
CLChristine L. Lau
Christine L. Lau
MMMuhammad M. Mohiuddin
Muhammad M. Mohiuddin
A 57-year-old man with nonischemic cardiomyopathy who was dependent on venoarterial extracorporeal membrane oxygenation (ECMO) and was not a candidate for standard therapeutics, including a traditional allograft, received a heart from a genetically modified pig source animal that had 10 individual gene edits. Immunosuppression was based on CD40 blockade. The patient was weaned from ECMO, and the xenograft functioned normally without apparent rejection. Sudden diastolic thickening and failure of the xenograft occurred on day 49 after transplantation, and life support was withdrawn on day 60. On autopsy, the xenograft was found to be edematous, having nearly doubled in weight. Histologic examination revealed scattered myocyte necrosis, interstitial edema, and red-cell extravasation, without evidence of microvascular thrombosis — findings that were not consistent with typical rejection. Studies are under way to identify the mechanisms responsible for these changes. (Funded by the University of Maryland Medical Center and School of Medicine.)

11 January 2022 in Reviews in Cardiovascular Medicine
Verified
Journal Article
Open access
MAMorcos A. Awad
Morcos A. Awad
ASAakash Shah
Aakash Shah
BGBartley P Griffith
Bartley P Griffith
The first human heart transplantation was performed by Christian Barnard in 1967. While the technical aspect had been worked out, allograft rejection was a major limitation in the early days of heart transplant. The discovery of cyclosporine revolutionized the field and led to the modern era of transplant. Heart transplantation now offers the best survival benefit for patients with end-stage heart failure with a median survival over 12 years. However, there are still limitations including the impact of limited availability of graft, graft dysfunction, and rejection, and long-term non-cardiac complications. This review serves as an update on the short- and long-term outcomes following heart transplantation focusing on the new donor allocation system, efforts to expand the donor pool, primary graft dysfunction, acute cellular and antibody-mediated rejection, cardiac allograft vasculopathy, and post-transplant malignancy and renal dysfunction.

1 July 2024 in Physiological Reviews
Verified
Journal Article
Open access
LPLeigh Peterson
Leigh Peterson
MYMagdi Yacoub
Magdi Yacoub
DADavid Ayares
David Ayares
KYKazuhiko Yamada
Kazuhiko Yamada
DEDaniel Eisenson
Daniel Eisenson
MRMartine Rothblatt
Martine Rothblatt
The collective efforts of scientists over multiple decades have led to advancements in molecular and cellular biology-based technologies including genetic engineering and animal cloning that are now being harnessed to enhance the suitability of pig organs for xenotransplantation into humans. Using organs sourced from pigs with multiple gene deletions and human transgene insertions, investigators have overcome formidable immunological and physiological barriers in pig-to-nonhuman primate (NHP) xenotransplantation and achieved prolonged pig xenograft survival. These studies informed the design of Revivicor’s (Revivicor Inc, Blacksburg, VA) genetically engineered pigs with 10 genetic modifications (10 GE) (including the inactivation of 4 endogenous porcine genes and insertion of 6 human transgenes), whose hearts and kidneys have now been studied in preclinical human xenotransplantation models with brain-dead recipients. Additionally, the first two clinical cases of pig-to-human heart xenotransplantation were recently performed with hearts from this 10 GE pig at the University of Maryland. Although this review focuses on xenotransplantation of hearts and kidneys, multiple organs, tissues, and cell types from genetically engineered pigs will provide much-needed therapeutic interventions in the future.

1 April 2014 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
PSP.G. Sanchez
P.G. Sanchez
RDR.D. Davis
R.D. Davis
FDF. D’ovidio
F. D’ovidio
ECE. Cantu
E. Cantu
MWM. Weyant
M. Weyant
BGBartley P Griffith
Bartley P Griffith

7 July 2022 in JACC: Case Reports
Verified
Journal Article
Open access
ASAakash Shah
Aakash Shah
CGCorbin E. Goerlich
Corbin E. Goerlich
CPChetan Pasrija
Chetan Pasrija
JHJeffrey Hirsch
Jeffrey Hirsch
SFStacy Fisher
Stacy Fisher
BGBartley P Griffith
Bartley P Griffith
Cardiac xenotransplantation has been proposed to bridge the gap between supply and demand for patients with end-stage heart failure requiring transplantation. However, differences in pig anatomy compared with human anatomy require modification of the surgical approach. In addition, careful consideration should be given to size matching before transplantation. (Level of Difficulty: Advanced.)

5 November 2021 in Journal of Biomechanical Engineering
Verified
Journal Article
Closed access
PDF file
DONG HANDONG HAN
DONG HAN
JZJiafeng Zhang
Jiafeng Zhang
BGBartley P Griffith
Bartley P Griffith
Zhongjun Jon WuZhongjun Jon Wu
Zhongjun Jon Wu
Shear-induced platelet activation is one of the critical outcomes when blood is exposed to elevated shear stress. Excessively activated platelets in the circulation can lead to thrombus formation and platelet consumption, resulting in serious adverse events such as thromboembolism and bleeding. While experimental observations reveal that it is related to the shear stress level and exposure time, the underlying mechanism of shear-induced platelet activation is not fully understood. Various models have been proposed to relate shear stress levels to platelet activation, yet most are modified from the empirically calibrated power-law model. Newly developed multiscale platelet models are tested as a promising approach to capture a single platelet's dynamic shape during activation, but it would be computationally expensive to employ it for a large-scale analysis. This paper summarizes the current numerical models used to study the shear-induced platelet activation and their computational applications in the risk assessment of a particular flow pattern and clot formation prediction.